Fan Q, Yang J, Wang G
Department of Intensive Care, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Clin Transl Oncol. 2014 Feb;16(2):191-9. doi: 10.1007/s12094-013-1061-x. Epub 2013 Jun 8.
Malignant peripheral nerve sheath tumors (MPNST) are relatively rare sarcomas and poorly understood. We sought to find clinicopathological and molecular predictors of survival for Chinese MPNST patients.
Clinical information from 146 MPNST patients treated in the Tianjin Medical University Cancer Institute and Hospital was collected and 56 cases of formalin-fixed and paraffin-embedded tissues were available for immunohistochemical examination of expression of hepatocyte growth factor receptor (c-MET), E3 ubiquitin-protein ligase Mdm2 (MDM2), and TP53.
The 5-year tumor-free survival rate was 24 % and the median tumor-free survival time was 25.64 months. The 5-year overall survival rate was 57 % and the median overall survival time was 132.57 months. The expression patterns of c-MET, TP53, and MDM2 were heterogeneous with total positivity rates of 82.1 % (46/56), 55.4 % (31/56), and 73.2 % (41/56), respectively. The univariate analysis not only showed that tumor size, Neurofibromin 1 (NF1) status, the American Joint Committee on Cancer (AJCC) stage, surgery, MDM2 expression, and TP53 expression had significant correlation with the tumor-free survival, but also demonstrated that radiotherapy, chemotherapy, tumor size, and NF1 status had significant correlation with the overall survival. Even though multivariate analysis found no independent prognostic predictor of MPNST, tumor size and NF1 status had significant correlation with the tumor-free survival and overall survival of MPNST patients.
With this, the largest documented Chinese cohort, our data supply powerful Chinese evidence of the prognostic role of tumor size and NF1 status in MPNST.
恶性外周神经鞘膜瘤(MPNST)是相对罕见的肉瘤,人们对其了解较少。我们试图找出中国MPNST患者生存的临床病理和分子预测指标。
收集了天津医科大学肿瘤医院治疗的146例MPNST患者的临床信息,56例福尔马林固定石蜡包埋组织可用于免疫组化检测肝细胞生长因子受体(c-MET)、E3泛素蛋白连接酶Mdm2(MDM2)和TP53的表达。
5年无瘤生存率为24%,中位无瘤生存时间为25.64个月。5年总生存率为57%,中位总生存时间为132.57个月。c-MET、TP53和MDM2的表达模式具有异质性,总阳性率分别为82.1%(46/56)、55.4%(31/56)和73.2%(41/56)。单因素分析不仅显示肿瘤大小、神经纤维瘤蛋白1(NF1)状态、美国癌症联合委员会(AJCC)分期、手术、MDM2表达和TP53表达与无瘤生存显著相关,还表明放疗、化疗、肿瘤大小和NF1状态与总生存显著相关。尽管多因素分析未发现MPNST的独立预后预测指标,但肿瘤大小和NF1状态与MPNST患者的无瘤生存和总生存显著相关。
通过这个最大的中国文献报道队列,我们的数据提供了有力的中国证据,证明肿瘤大小和NF1状态在MPNST中的预后作用。